CJC-1295 without DAC: Research, Handling and Batch Documentation

Identity and research status

Backbone

Human GHRH(1-29) with four amino acid substitutions

Key Substitution

D-alanine at position 2, blocking DPP-4 cleavage

Conjugation Group

None. This is the defining difference from the DAC-bearing construct

Molecular Weight

Approximately 3368 g/mol

Length

29 amino acids, C-terminally amidated

Also Known As

Modified GRF(1-29), mod GRF 1-29, CJC-1295 no DAC

Half-life

Approximately 30 minutes

Receptor Target

GHRH receptor on pituitary somatotrophs

Secretion Pattern

Pulsatile

Appearance

White lyophilised powder

Mechanism, in brief

CJC-1295 without DAC is the tetrasubstituted GHRH(1-29) peptide with no albumin-binding group attached. It is more accurately named modified GRF(1-29), and that name is worth preferring, because calling it CJC-1295 invites the assumption that it shares the pharmacokinetics of the DAC-bearing construct it is named after. It does not, and the difference is roughly two orders of magnitude in half-life.

1. Enzymatic protection. Four substitutions on the GHRH(1-29) backbone, with D-alanine at position 2 blocking the dipeptidyl peptidase-4 cleavage that destroys the activating N-terminal determinant.
2. No albumin binding. The defining absence. Without the maleimidopropionyl DAC group there is no covalent albumin conjugation, so clearance remains rapid.
3. GHRH receptor agonism. Full agonism at the GHRH receptor on pituitary somatotrophs, signalling through Gs and cyclic AMP.
4. Pulsatile release. Rapid clearance means brief receptor stimulation and a discrete growth hormone pulse rather than sustained elevation.
5. Feedback preserved. Somatostatin tone and IGF-1 negative feedback remain intact, so the response is self-limiting in the way exogenous growth hormone administration is not.

The full research write-up, including the findings behind each claim and the model each came from, is on the CJC-1295 No DAC 10mg 10mg page.

Vial sizes available

Every size of CJC-1295 without DAC Volta lists, in stock or not. Each is a separate catalogue page with its own batch number and specification table.

• CJC-1295 No DAC 10mg 10mgBatch #: VPCN10100
  Restocking

Purity and batch documentation

Volta's release specification is >99% (HPLC). That is a threshold we set. >99% is the specification every batch is released to. The figure on a certificate is what a laboratory measured for one lot.

No third-party certificate has been published for CJC-1295 without DACyet. The certificates Volta does publish, with the laboratory's own verification link on each, are in the certificate archive.

Research on CJC-1295 without DAC

Handling and stability

Regulatory context

• the legal status of research peptides in Canada
• Health Canada's regulatory position

Primary sources

1. Soule S, King JA, Millar RP. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance. Journal of Clinical Endocrinology and Metabolism (1994). PMID 7962295
2. Teichman SL, Neale A, Lawrence B, et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism (2006). PMID 16352683
3. Achermann JC, Hindmarsh PC, Brook CG. The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin withdrawal in growth hormone secretion. Clinical Endocrinology (Oxford) (1999). PMID 10594518
4. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs (1999). PMID 18031173
5. Dominikowski A, Rękoś Z, et al.. The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis. Frontiers in Endocrinology (2026). PMID 42395176
6. Villegas Meza AD, Nocek M, et al.. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence and Safety. JBJS Reviews (2026). PMID 42160466